Cargando…

Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes

Influenza virus remains a threat because of its ability to evade vaccine-induced immune responses due to antigenic drift. Here, we describe the isolation, evolution, and structure of a broad-spectrum human monoclonal antibody (mAb), MEDI8852, effectively reacting with all influenza A hemagglutinin (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kallewaard, Nicole L., Corti, Davide, Collins, Patrick J., Neu, Ursula, McAuliffe, Josephine M., Benjamin, Ebony, Wachter-Rosati, Leslie, Palmer-Hill, Frances J., Yuan, Andy Q., Walker, Philip A., Vorlaender, Matthias K., Bianchi, Siro, Guarino, Barbara, De Marco, Anna, Vanzetta, Fabrizia, Agatic, Gloria, Foglierini, Mathilde, Pinna, Debora, Fernandez-Rodriguez, Blanca, Fruehwirth, Alexander, Silacci, Chiara, Ogrodowicz, Roksana W., Martin, Stephen R., Sallusto, Federica, Suzich, JoAnn A., Lanzavecchia, Antonio, Zhu, Qing, Gamblin, Steven J., Skehel, John J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967455/
https://www.ncbi.nlm.nih.gov/pubmed/27453466
http://dx.doi.org/10.1016/j.cell.2016.05.073
Descripción
Sumario:Influenza virus remains a threat because of its ability to evade vaccine-induced immune responses due to antigenic drift. Here, we describe the isolation, evolution, and structure of a broad-spectrum human monoclonal antibody (mAb), MEDI8852, effectively reacting with all influenza A hemagglutinin (HA) subtypes. MEDI8852 uses the heavy-chain VH6-1 gene and has higher potency and breadth when compared to other anti-stem antibodies. MEDI8852 is effective in mice and ferrets with a therapeutic window superior to that of oseltamivir. Crystallographic analysis of Fab alone or in complex with H5 or H7 HA proteins reveals that MEDI8852 binds through a coordinated movement of CDRs to a highly conserved epitope encompassing a hydrophobic groove in the fusion domain and a large portion of the fusion peptide, distinguishing it from other structurally characterized cross-reactive antibodies. The unprecedented breadth and potency of neutralization by MEDI8852 support its development as immunotherapy for influenza virus-infected humans.